Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Rosiglitazone–containing Medicines (Avandia/Avandamet) – Direct Healthcare Professional Communication issued by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
28/07/2010
Problem Or Issue:
Further to previous regulatory updates on cardiovascular risk with rosiglitazone, the Irish Medicines Board has issued a Direct Healthcare Professional Communication reinforcing existing recommendations about the use of rosiglitazone (Avandia/Avandamet) in the treatment of diabetes. The communication also provides information about new data currently being evaluated at EU level concerning rosiglitazone and cardiovascular risk.
Rosiglitazone Direct Healthcare Professional Communication
« Back
Date Printed: 19/08/2022